Neoadjuvant Treatment Modalities in Esophageal Cancer
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
Esophageal cancer is the most prevalent cancer globally with poor survival outcome. The
prognosis with surgery alone is poor, accounting for 30-40% of overall survival at 5 year.
Either neoadjuvant chemotherapy (nCT) or chemoradiotherapy (nCRT) has been shown as
efficatious therapy to improve patients outcomes in esophageal or esophagogastric junction
cancer as compared with surgery alone. The purpose of this study was to explore the optimal
neoadjuvant treatment modalities including PD-1/PD-L1 antibody or targeted drug for patients
with esophageal or esophagogastric junction cancer.